Skip to main content

Drug Interactions between atrasentan and Crixivan

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

indinavir atrasentan

Applies to: Crixivan (indinavir) and atrasentan

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of atrasentan, which is primarily metabolized by CYP450 3A4. When a single dose of atrasentan 10 mg was administered with ketoconazole, a potent CYP450 3A4 inhibitor, atrasentan systemic exposure (AUC) increased by 90%. The risk of adverse effects such as edema, hepatotoxicity and anemia may be increased with this combination. The interaction has not been studied with other, less potent CYP450 3A4 inhibitors.

MANAGEMENT: Caution is advised when atrasentan is used with potent CYP450 3A4 inhibitors. Patients should be monitored for edema, anemia and signs of hepatotoxicity such as nausea, vomiting, abdominal pain, dark urine, loss of appetite, itching and/or yellowing of the skin or eyes.

Drug and food interactions

Moderate

indinavir food

Applies to: Crixivan (indinavir)

Large amounts of food decreases the levels of indinavir in your body. Indinavir should be taken on an empty stomach, at least 1 hour before or 2 hours after a meal. This will make it easier for your body to absorb the medication. Take indinavir with a full glass (8 ounces) of water or skim milk. You may also drink juice, coffee, or tea with this medication. Drink at least 6 glasses of water each day to prevent kidney stones while you are taking indinavir. If you prefer to take the medication with food, eat only a light meal, such as dry toast with jelly, or corn flakes with skim milk and sugar. Avoid eating a high-fat meal.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.